Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOMCAD: Lomerizine for Prevention of Recurrent Cerebral Ischemic Events in CADASIL
jRCTs051220072Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Aug 2022
- Countries
- 1
01
Overview
Open-label, single-arm trial in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) and ischemic stroke, sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Symptomatic cerebral ischemic events during 24 months. Started Aug 2022; status: completed.
02
Conditions
cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)ischemic stroke
Beyond the preview
Go deeper on jRCTs051220072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051220072.